Safety and Efficacy of PCSK9 Inhibitor Treatment in Heart Transplant Patients

被引：10
|
作者：
Di Nora, Concetta [1 ]
Sponga, Sandro [1 ]
Livi, Ugolino [1 ]
机构：
[1] Azienda Sanit Univ Integrata Udine, Dept Cardiothorac Sci, Udine, Italy
来源：
TRANSPLANTATION | 2019年 / 103卷 / 03期
关键词：
RISK;
D O I：
10.1097/TP.0000000000002520
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：E58 / E58
页数：1
相关论文
共 50 条
  • [21] Association between serum PCSK9 and coronary heart disease in patients with type 2 diabetes mellitus
    Huang, Juan
    Gu, Jun-Xu
    Wang, Kun
    Zhang, Ai-Min
    Hong, Ting-Ting
    Li, Shan-Shan
    Yao, Xiao-Qin
    Yang, Ming
    Yin, Yue
    Zhang, Na
    Su, Ming
    Hu, Jia-Jia
    Zhang, Xue-Zhi
    Jia, Mei
    DIABETOLOGY & METABOLIC SYNDROME, 2023, 15 (01)
  • [22] The Pharmacologic Role and Clinical Utility of PCSK9 Inhibitors for the Treatment of Hypercholesterolemia
    White, C. Michael
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2018, 23 (04) : 301 - 308
  • [23] Cardiovascular Efficacy and Safety of PCSK9 Inhibitors: Systematic Review and Meta-analysis Including the ODYSSEY OUTCOMES Trial
    Turgeon, Ricky D.
    Tsuyuki, Ross T.
    Gyenes, Gabor T.
    Pearson, Glen J.
    CANADIAN JOURNAL OF CARDIOLOGY, 2018, 34 (12) : 1600 - 1605
  • [24] Metabolomic Consequences of Genetic Inhibition of PCSK9 Compared With Statin Treatment
    Sliz, Eeva
    Kettunen, Johannes
    Holmes, Michael V.
    Williams, Clare Oliver
    Boachie, Charles
    Wang, Qin
    Maennikkoe, Minna
    Sebert, Sylvain
    Walters, Robin
    Lin, Kuang
    Millwood, Iona Y.
    Clarke, Robert
    Li, Liming
    Rankin, Naomi
    Welsh, Paul
    Delles, Christian
    Jukema, J. Wouter
    Trompet, Stella
    Ford, Ian
    Perola, Markus
    Salomaa, Veikko
    Jaervelin, Marjo-Riitta
    Chen, Zhengming
    Lawlor, Debbie A.
    Ala-Korpela, Mika
    Danesh, John
    Davey Smith, George
    Sattar, Naveed
    Butterworth, Adam
    Wuertz, Peter
    CIRCULATION, 2018, 138 (22) : 2499 - 2512
  • [25] Healthy Individuals Carrying the PCSK9 p.R46L Variant and Familial Hypercholesterolemia Patients Carrying PCSK9 p.D374Y Exhibit Lower Plasma Concentrations of PCSK9
    Humphries, Steve E.
    Neely, R. Dermot G.
    Whittall, Roslyn A.
    Troutt, Jason S.
    Konrad, Robert J.
    Scartezini, Marileia
    Li, Ka Wah
    Cooper, Jackie A.
    Acharya, Jayshree
    Neil, Andrew
    CLINICAL CHEMISTRY, 2009, 55 (12) : 2153 - 2161
  • [26] PCSK9 inhibitor therapy: A systematic review and meta-analysis of metabolic and cardiovascular outcomes in patients with diabetes
    Monami, Matteo
    Sesti, Giorgio
    Mannucci, Edoardo
    DIABETES OBESITY & METABOLISM, 2019, 21 (04) : 903 - 908
  • [27] PCSK9 deficiency rewires heart metabolism and drives heart failure with preserved ejection fraction
    Da Dalt, Lorenzo
    Castiglioni, Laura
    Baragetti, Andrea
    Audano, Matteo
    Svecla, Monika
    Bonacina, Fabrizia
    Pedretti, Silvia
    Uboldi, Patrizia
    Benzoni, Patrizia
    Giannetti, Federica
    Barbuti, Andrea
    Pellegatta, Fabio
    Indino, Serena
    Donetti, Elena
    Sironi, Luigi
    Mitro, Nico
    Catapano, Alberico Luigi
    Norata, Giuseppe Danilo
    EUROPEAN HEART JOURNAL, 2021, 42 (32) : 3078 - 3090
  • [28] PCSK9 inhibitor, ezetimibe, and bempedoic acid: Evidence-based therapies for statin-intolerant patients
    Gunta, Satya Preetham
    O'Keefe, James H.
    O'Keefe, Evan L.
    Lavie, Carl J.
    PROGRESS IN CARDIOVASCULAR DISEASES, 2023, 79 : 12 - 18
  • [29] PCSK9 Levels Are Raised in Chronic HCV Patients with Hepatocellular Carcinoma
    Fasolato, Silvano
    Pigozzo, Sabrina
    Pontisso, Patrizia
    Angeli, Paolo
    Ruscica, Massimiliano
    Savarino, Edoardo
    De Martin, Sara
    Lupo, Maria Giovanna
    Ferri, Nicola
    JOURNAL OF CLINICAL MEDICINE, 2020, 9 (10) : 1 - 10
  • [30] How many familial hypercholesterolemia patients are eligible for PCSK9 inhibition?
    Masana, Luis
    Plana, Nuria
    Perez-Calahorra, Sofia
    Ibarretxe, Daiana
    Lamiquiz-Moneo, Itziar
    Pedro-Botet, Juan
    Suarez-Tembra, Manuel
    Valdivielso, Pedro
    Ortega, Emilio
    Civeira, Fernando
    ATHEROSCLEROSIS, 2017, 262 : 107 - 112
12345